ICON Plc (ICLR)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:ICON Plc (ICLR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012301
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:53
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アイルランド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥34,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥69,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥103,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
ICON plc (ICON) is a contract research organization (CRO) that provides outsourced development services to the biotechnology, pharmaceutical and medical device industries worldwide. It provides a range of specialized services that span the entire lifecycle of product development. The company’s service portfolio includes adaptive trials, biosimilars, clinical research services, commercialization and outcomes, consulting, functional services provision, medical imaging, laboratory services, resourcing solutions and strategic support and tactical solutions for traditional, in vitro diagnostic, and software devices. The company offers research services in areas such as cancer, genomics, central nervous system, cardiovascular, endocrine and metabolic disorders, gastrointestinal, medical device, nonalcoholic steatohepatitis (NASH), ophthalmology, rare and orphan diseases, transplant and immunology, vaccines, women’s health therapeutics and other therapeutic areas. ICON is headquartered in Dublin, Ireland.

ICON Plc (ICLR) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
ICON Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
ICON Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
ICON Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
ICON Plc, Medical Devices Deals, 2011 to YTD 2017 9
ICON Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
ICON Plc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Icon Completes Acquisition Of Clinical Trial Services Business From Cross Country Healthcare For Up To US$56 Million 11
Venture Financing 13
Aptiv Solutions Raises US$5.7 Million In Venture Financing 13
Partnerships 14
ICON Forms Joint Venture With ACRONET 14
Aptiv Solutions Enters Into Joint Venture Agreement With Cancer Genetics 15
Merger 16
Inclinix Merges With PMG Research 16
Licensing Agreements 17
Aptiv Solutions Enters Into Licensing Agreement With Tessella For FACTS, Adaptive Trial Design Software 17
Acquisition 18
ICON Acquires Mapi 18
Icon Acquires Clinical Research Management 19
Icon Acquires PMG Research from Frontier Capital 20
ICON Acquires MediMedia Pharma Solutions for USD120 Million 21
Icon Completes Acquisition Of Aptiv Solutions For US$143.5 Million 22
Icon Completes Acquisition Of BeijingWits Medical Consulting, Contract Research Organization 24
Aptiv Solutions Completes Acquisition Of SRA Global Clinical From SRA International 25
ICON Plc – Key Competitors 26
ICON Plc – Key Employees 27
ICON Plc – Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Recent Developments 31
Financial Announcements 31
Oct 26, 2017: ICON Reports Third Quarter 2017 Results 31
Jul 27, 2017: ICON Reports Second Quarter 2017 Results 32
Apr 27, 2017: ICON Reports First Quarter 2017 Results 33
Feb 16, 2017: ICON Reports Fourth Quarter and Full Year 2016 Results 34
Jan 09, 2017: ICON Issues Financial Guidance for Full Year 2017 35
Oct 20, 2016: ICON Reports Third Quarter 2016 Results 36
Jul 26, 2016: ICON Reports Second Quarter 2016 Results 37
Apr 26, 2016: ICON Reports First Quarter 2016 Results 38
Feb 23, 2016: CON Reports Fourth Quarter and Full Year 2015 Results and Issues 2016 Earnings Guidance 39
Corporate Communications 40
Nov 17, 2017: ICON Announces Appointment of Ms. Joan Garahy to Board of Directors 40
Oct 04, 2017: ICON Announces Appointment of Mr. Eugene McCague to Board of Directors 41
Oct 24, 2016: ICON Announces Appointment of Mr. Ronan Murphy to Board of Directors 42
Oct 20, 2016: ICON Announces Executive Leadership Transition 43
Mar 29, 2016: Mr. Thomas Lynch Notifies ICON of His Retirement as Chairman and That He Will Not Stand for Re-Election to the Board of Directors at the Annual General Meeting 44
Government and Public Interest 45
Jun 15, 2016: New Research from ICON Demonstrates Support for ‘Bring Your Own Device’ Approach in Clinical Trials 45
Product News 46
Nov 21, 2017: ICON Launches FIRECREST Pre-Screen to Improve the Speed and Accuracy of Identifying Eligible Patients for Screening 46
Nov 07, 2017: ICON contributes to major European research study that aims to improve treatment for traumatic brain injury 47
Jun 07, 2016: ICON-sponsored research by Carnegie Mellon University validates shorter and simpler patient consent processes in clinical trials 48
Feb 20, 2017: ICON Selected by the FDA to Validate Patient-Reported Outcome Endpoints for Antibacterial Drug Trials 49
Jan 19, 2016: ICON Releases Flex Advantage to Enhance Patient Randomisation and Clinical Supply Management in Clinical Trials 50
Other Significant Developments 51
Nov 06, 2017: ICON Reveals Voice-Assistant Applications for Clinical Trials at ISPOR Annual European Congress 51
Oct 27, 2017: ICON and ICHOM unveil the world’s first global patient outcomes benchmarking platform 52
Appendix 53
Methodology 53
About GlobalData 53
Contact Us 53
Disclaimer 53

List of Tables
ICON Plc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
ICON Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 2
ICON Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
ICON Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
ICON Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
ICON Plc, Medical Devices Deals, 2011 to YTD 2017 9
ICON Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Icon Completes Acquisition Of Clinical Trial Services Business From Cross Country Healthcare For Up To US$56 Million 11
Aptiv Solutions Raises US$5.7 Million In Venture Financing 13
ICON Forms Joint Venture With ACRONET 14
Aptiv Solutions Enters Into Joint Venture Agreement With Cancer Genetics 15
Inclinix Merges With PMG Research 16
Aptiv Solutions Enters Into Licensing Agreement With Tessella For FACTS, Adaptive Trial Design Software 17
ICON Acquires Mapi 18
Icon Acquires Clinical Research Management 19
Icon Acquires PMG Research from Frontier Capital 20
ICON Acquires MediMedia Pharma Solutions for USD120 Million 21
Icon Completes Acquisition Of Aptiv Solutions For US$143.5 Million 22
Icon Completes Acquisition Of BeijingWits Medical Consulting, Contract Research Organization 24
Aptiv Solutions Completes Acquisition Of SRA Global Clinical From SRA International 25
ICON Plc, Key Competitors 26
ICON Plc, Key Employees 27
ICON Plc, Subsidiaries 28

★海外企業調査レポート[ICON Plc (ICLR)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Citizens Electric Corporation:発電所・企業SWOT分析
    Citizens Electric Corporation - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key …
  • Immunicom Inc:医療機器:M&Aディール及び事業提携情報
    Summary Immunicom Inc (Immunicom) is a specialty biotechnology company that develops non-pharmaceutical therapies for oncology and autoimmune diseases. The company offers immune inhibitors that play a key role in protecting tumors from the body’s natural immune mechanisms. It proprietary Immunophere …
  • Colt Technology Services Group Ltd:企業の戦略的SWOT分析
    Colt Technology Services Group Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Haci Omer Sabanci Holding A.S. (SAHOL)-エネルギー分野:企業M&A・提携分析
    Summary Haci Omer Sabanci Holding A.S. (Sabanci) is an industrial and financial conglomerate. The company carries out banking, insurance, energy, retail, cement, insurance, automotive, tire and tire reinforcement materials businesses. The company has partnerships with various multinational business …
  • Beximco Pharmaceuticals Ltd (BXPHARMA):企業の財務・戦略的SWOT分析
    Summary Beximco Pharmaceuticals Ltd (Beximco Pharma) is a manufacturer and exporter of generic medicines and active pharmaceutical ingredients (APIs). The company offers products in the therapeutic areas of allergic disorders, analgesics and antipyretic, anti-infectives, cardiovascular, central nerv …
  • Gemini Corp (GKX)-石油・ガス分野:企業M&A・提携分析
    Summary Gemini Corporation (Gemini) is an oil and gas engineering company that provides engineering, field and environmental solutions. The company offers services including project management systems, fabrication, maintenance, procurement, construction, land, environmental, regulatory, and reclamat …
  • Secure Energy Services Inc (SES):石油・ガス:M&Aディール及び事業提携情報
    Summary Secure Energy Services Inc. (Secure Energy) is an energy services company. It provides specialized services to upstream oil and natural gas companies operating in the Western Canadian Sedimentary Basin (WCSB) and North Dakota. The company assists these companies with the handling, processing …
  • Novozymes AS (NZYM B):企業の財務・戦略的SWOT分析
    Novozymes AS (NZYM B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • PHX Minerals Inc (PHX):企業の財務・戦略的SWOT分析
    PHX Minerals Inc (PHX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Kumho Petrochemical Co Ltd (011780):企業の財務・戦略的SWOT分析
    Kumho Petrochemical Co Ltd (011780) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Lennox International Inc (LII):企業の財務・戦略的SWOT分析
    Lennox International Inc (LII) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Associated Alcohols & Breweries Limited.:企業の戦略・SWOT・財務分析
    Associated Alcohols & Breweries Limited. - Strategy, SWOT and Corporate Finance Report Summary Associated Alcohols & Breweries Limited. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Nymox Pharmaceutical Corp (NYMX)-医療機器分野:企業M&A・提携分析
    Summary Nymox Pharmaceutical Corp (Nymox) is a biopharmaceutical company that undertakes the research and development of therapeutics and diagnostics devices to target the unmet needs of the aging population. The company markets diagnostic products for measuring tobacco product exposure and for the …
  • Agilent Technologies Inc (A)-医療機器分野:企業M&A・提携分析
    Summary Agilent Technologies Inc (Agilent) is a provider of instruments, reagents, software, services and consumables for comprehensive laboratory workflow. Its product portfolio comprises atomic absorption systems, bioanalyzers, gene expression microarrays and automation systems, among others. The …
  • WABCO Holdings Inc.:企業の戦略・SWOT・財務分析
    WABCO Holdings Inc. - Strategy, SWOT and Corporate Finance Report Summary WABCO Holdings Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • HDI-Global SE:企業の戦略・SWOT・財務情報
    HDI-Global SE - Strategy, SWOT and Corporate Finance Report Summary HDI-Global SE - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Biovista Inc-製薬・医療分野:企業M&A・提携分析
    Summary Biovista Inc (Biovista) is a drug development company that provides COSS platform technology support in uncovering non-obvious correlations between drugs. The company’s products are used for the treatment of neurodegenerative diseases, epilepsy, oncology and orphan diseases. It offers servic …
  • Lavendon Group Plc:企業の戦略・SWOT・財務情報
    Lavendon Group Plc - Strategy, SWOT and Corporate Finance Report Summary Lavendon Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Meridian Energy Limited:企業の戦略・SWOT・財務情報
    Meridian Energy Limited - Strategy, SWOT and Corporate Finance Report Summary Meridian Energy Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • First Data Corp (FDC):企業の財務・戦略的SWOT分析
    First Data Corp (FDC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆